The TP63 gene gives rise to protein isoforms with different properties and functions due to the presence (TAp63) or absence (ΔNp63) of an N-terminal p53-like transactivation domain. Immunohistochemistry for p63 has clinical value for certain tumour types, but investigations have been hampered by a lack of well characterized antibodies and the inability to discriminate between these N-terminal isoforms with opposite functional properties. We have extensively characterized a series of monoclonal antibodies to recombinant human TAp63 and two commercial p63 monoclonals by Western blot, immunostaining and phage display epitope mapping. Twenty-eight of 29 (96.6 %) novel monoclonals that recognized all p63 isoforms showed substantial cross-reactivity with p73, as did the commercial antibody, 4A4. One novel clone, PANp63-6.1, showed slight cross-reaction with p73 by Western blotting but not immunohistochemistry and the SFI-6 monoclonal did not cross-react with p73 or p53. Phage display revealed that the PANp63-6.1 epitope has one amino acid difference between p63 and p73, the 4A4 epitope is identical in both, whereas the SFI-6 epitope is unique to p63, accounting for these findings. We also produced and characterized a TAp63-specific clone that does not recognize p53 or p73, and we prepared polyclonal sera specific for ΔNp63 isoforms. Immunohistochemistry demonstrated that TAp63 is expressed in a variety of epithelial and other cell types during development, often in a converse pattern to ΔNp63, but has a very limited expression in normal adult tissues and is independent of ΔNp63. TAp63 was expressed in 17.6 % of squamous cancers of cervix that expressed p63, unlike normal cervix where TAp63 was not expressed. TAp63 did not associate with proliferative index, but cervical carcinomas with TAp63 expression showed improved survival. These data highlight the need for rigorous antibody characterization and indicate that p63-isoform identification may improve the clinical value of p63 expression analyses.

Regional Centre for Applied Molecular Oncology Masaryk Memorial Cancer Institute Zluty kopec 7 656 53 Brno Czech Republic

Zobrazit více v PubMed

Hum Pathol. 2005 Feb;36(2):187-94 PubMed

Am J Pathol. 2011 Mar;178(3):1350-60 PubMed

Oral Oncol. 2010 Sep;46(9):667-71 PubMed

Mod Pathol. 2011 Oct;24(10):1348-59 PubMed

Nature. 2010 Oct 21;467(7318):986-90 PubMed

Mod Pathol. 2006 Oct;19(10):1358-68 PubMed

J Pathol. 2002 Dec;198(4):417-27 PubMed

Nature. 2006 Nov 30;444(7119):624-8 PubMed

Nat Med. 2009 Oct;15(10):1179-85 PubMed

Cell Cycle. 2007 Feb 1;6(3):274-85 PubMed

Virchows Arch. 2005 Oct;447(4):688-94 PubMed

PLoS One. 2012;7(1):e30206 PubMed

Mod Pathol. 2011 Nov;24(11):1451-61 PubMed

J Biol Chem. 2011 May 6;286(18):15918-28 PubMed

Carcinogenesis. 2008 Feb;29(2):273-81 PubMed

Am J Clin Pathol. 2012 Jun;137(6):946-56 PubMed

Cancer Res. 2006 Apr 15;66(8):3981-6 PubMed

Cancer Invest. 2007 Sep;25(6):464-9 PubMed

Virchows Arch. 2003 Aug;443(2):175-83 PubMed

Histopathology. 2006 Aug;49(2):211-4 PubMed

Genes Dev. 2004 Jan 15;18(2):126-31 PubMed

Hum Pathol. 2004 Apr;35(4):465-73 PubMed

Am J Surg Pathol. 2011 Jan;35(1):15-25 PubMed

ORL J Otorhinolaryngol Relat Spec. 2010;72(6):319-24 PubMed

Am J Pathol. 2002 Oct;161(4):1199-206 PubMed

Cell Cycle. 2005 Oct;4(10):1313-5 PubMed

Mol Cell Biol. 2005 Jul;25(14):6154-64 PubMed

Mod Pathol. 2012 Mar;25(3):405-15 PubMed

Cancer Res. 2003 Nov 1;63(21):7113-21 PubMed

Cell Mol Biol Lett. 2011 Jun;16(2):296-327 PubMed

Cell Cycle. 2009 Nov 15;8(22):3702-6 PubMed

Cold Spring Harb Perspect Biol. 2010 Jun;2(6):a001198 PubMed

Int J Oncol. 2004 Jul;25(1):27-35 PubMed

EMBO J. 2005 Jul 6;24(13):2458-71 PubMed

J Clin Invest. 2007 May;117(5):1370-80 PubMed

Am J Clin Pathol. 2011 Nov;136(5):762-6 PubMed

Cancer Res. 2009 Dec 15;69(24):9263-70 PubMed

Histopathology. 2004 Apr;44(4):403-4 PubMed

Breast Cancer Res Treat. 2010 Aug;122(3):765-75 PubMed

Proc Natl Acad Sci U S A. 2000 May 9;97(10):5462-7 PubMed

Nat Cell Biol. 2009 Dec;11(12):1451-7 PubMed

J Clin Pathol. 2007 Jan;60(1):35-42 PubMed

Histopathology. 2012 Mar;60(4):597-608 PubMed

Annu Rev Pathol. 2010;5:349-71 PubMed

Head Neck. 2011 Oct;33(10):1458-66 PubMed

Gynecol Oncol. 2003 Nov;91(2):346-53 PubMed

Histopathology. 2006 Jul;49(1):10-21 PubMed

Clin Cancer Res. 2003 Nov 15;9(15):5501-7 PubMed

J Pathol. 2005 Jul;206(3):337-45 PubMed

TAp73 and ΔTAp73 isoforms show cell-type specific distributions and alterations in cancer

Re-appraising the evidence for the source, regulation and function of p53-family isoforms

DNA Demethylation Switches Oncogenic ΔNp63 to Tumor Suppressive TAp63 in Squamous Cell Carcinoma

TAp63 and ΔNp63 (p40) in prostate adenocarcinomas: ΔNp63 associates with a basal-like cancer stem cell population but not with metastasis

TAp73β Can Promote Hepatocellular Carcinoma Dedifferentiation

∆Np63/p40 correlates with the location and phenotype of basal/mesenchymal cancer stem-like cells in human ER+ and HER2+ breast cancers

STAT3, stem cells, cancer stem cells and p63

p63 isoforms in triple-negative breast cancer: ΔNp63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival

ΔNp63α expression induces loss of cell adhesion in triple-negative breast cancer cells

ΔNp63 regulates cell proliferation, differentiation, adhesion, and migration in the BL2 subtype of basal-like breast cancer

A global analysis of the complex landscape of isoforms and regulatory networks of p63 in human cells and tissues